Background: Transcatheter aortic valve replacement (TAVR) is an alternative to
| INTRODUCTION
Since transcatheter aortic valve replacement (TAVR) was first approved by the US Food and Drug Administration (FDA) in November 2011 for the treatment of severe aortic stenosis in patients not considered candidates for surgical aortic valve replacement (SAVR), there has been steady expansion of criteria for use based on data from prospective randomized clinical trials. [1] [2] [3] [4] [5] Today, TAVR is no longer just for inoperable patients; it is now FDA-approved for the treatment of severe aortic stenosis in patients who are at extreme, high, and intermediate risk for mortality and morbidity from SAVR as determined by a Heart Team.
The most recent update from the Society of Thoracic Surgeons (STS) Adult Cardiac Surgical Database (ACSD) revealed a "meteoric" rise in TAVR volume since the database began capturing this procedure in 2012. 6 A previous study from the Michigan Society of Thoracic and Cardiovascular Surgeons Quality Collaborative (MSTCVS-QC) showed that overall SAVR volume in Michigan increased in the early years of TAVR implementation. 7 This study builds on the previous study by utilizing the MSTCVS-QC database to examine more recent trends in aortic valve replacement (AVR) in Michigan, determine factors that influenced trends, compare patient characteristics between those undergoing SAVR and TAVR, and predict future trends based on known factors.
| PATIENTS AND METHODS
The MSTCVS-QC is a statewide database of collective surgical cases and associated perioperative, operative, and outcomes data entered into the STS ACSD with state-specific data fields. patients were high risk, and 1400 patients were extreme risk.
Comparison of patient characteristics between SAVR and TAVR patients stratified by STS PROM is shown in Table 1 and by Heart
Team-designated risk category in Table 2 (10) 58 (12) 0.1836 55 (12) 55 (13) 0.2224
50 (14) 52 (15) 0.0023
47 (14) 47 (16) Figure 4A ); this trend is expected to continue. FDA approval of TAVR in low-risk patients with severe aortic stenosis is anticipated.
Based on the fact that the majority of patients undergoing SAVR are low-risk patients, we will likely continue to see a rapid increase in TAVR volume, perhaps this time accompanied by the beginning of a more dramatic decline in SAVR volume. Continued refinement of risk assessment tools to appropriately assess risk of SAVR versus TAVR, especially in younger patients for whom long-term valve durability and the effect of permanent pacemaker placement are a concern, will become even more important as we analyze long-term outcomes and recommend therapy decisions to our patients.
Our analysis is limited by its retrospective and observational nature and use of a large database that does not allow us to more closely examine data at the individual patient level. Missing data points for patient variables may have affected our ability to accurately detect differences between SAVR and TAVR patients. Furthermore, we did not examine the effect of same-day admissions and the "minimalist approach" to TAVR on TAVR volumes. 10, 11 Finally, short-(30-day) and long-term outcomes were not reported following TAVR to determine whether better patient selection by Heart Teams improved survival, as has been reported in other series, so that patients do not die from, as opposed to with, aortic stenosis. [11] [12] [13] 
